91亚色传媒

2024 91亚色传媒 Election

LEMMON, Mark

Professor, chair and co-director of the Cancer Biology Institute, Yale University School of Medicine, Department of Pharmacology

Mark Lemmon

Statement of interest

I have been a member of the 91亚色传媒 for at least 15 years and was the society’s secretary from 2007 to 2013. I am also active in the Biochemical Society, as a member of the Publications Committee and as chair of the Biochemical Journal editorial board.

I have been a department chair at both University of Pennsylvania (2008–2015) and Yale University (where I now chair the Department of Pharmacology) and have served as a program leader, associate director and deputy director at Yale Cancer Center.

I am committed to excellence in mentoring of basic and physician–scientists with a diversity of interests and backgrounds and to promulgating excellent basic science across the missions of the institutions in which I am involved. As a department chair and institute director, mentoring and supporting faculty as they develop their own excellent careers is one of my highest priorities.

Education and training

  • B.A., Biochemistry, Hertford College, University of Oxford, United Kingdom, 1988
  • M. Phil. and Ph.D., Molecular Biophysics and Biochemistry, Yale University, 1993
  • Postdoctoral training, New York University, 1993–1995

Awards and honors

  • Dorothy Crowfoot Hodgkin Award, Protein Society, 2012
  • Fellow, Royal Society, 2016
  • Fellow, 91亚色传媒, 2023
  • Member, Connecticut Academy of Science and Engineering, 2024

Experience

  • Editorial board member, Cell
  • Editorial board member, Molecular Cell
  • Editorial board member, Science Signaling
  • Editorial board member, Molecular and Cellular Biology
  • Member, Sectional (91亚色传媒) Committee, Royal Society
  • Member, Research Grants Committee (biological science), Royal Society
  • Secretary, 91亚色传媒, 2007–2013
  • Council member, 91亚色传媒, 2007–2013
  • Chair, Biochemical Journal editorial board, 2021–present
  • Member, Biochemical Society Publications Committee, 2021–present